Mallinckrodt Plc (Mallinckrodt) develops, produces, markets, and distributes specialty pharmaceutical products and therapies. The company offers branded pharmaceutical products for autoimmune and rare diseases in specialty areas such as rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers immunotherapy, oncology and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company offers specialty generic drugs and active pharmaceutical ingredients. Mallinckrodt markets branded products directly to physicians, specialty pharmacies, hospitals and ambulatory surgical centers; and also distributes branded and generic products through a network of drug distributors, specialty pharmaceutical distributors and retail pharmacy chains, among others. It has facilities in the US, Ireland, Japan and other countries. Mallinckrodt is headquartered in Dublin, Ireland.
Headquarters
Ireland
Address
College Business & Technology Park, Cruiserath, Blanchardstown, Dublin
Website
www.mallinckrodt.com
Telephone
353 1 8207940
No of Employees
2,800
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MNKKQ (OTC)
Revenue (2021)
$2.2B
-19.7%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
24.1%
(2021 vs 2020)
Market Cap*
$710,000
Net Profit Margin (2021)
XXX
5.5%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products |
|---|
| Specialty Brands: |
| Repository Corticotropin Injection |
| Nitricoxide |
| XXX |
| XXX |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | New Product Approvals | In June, the company received U.S. FDA Approval of StrataGraft |
| 2021 | New Product Approvals | In March, the company received U.S. FDA Approval of Updated Acthar Gel |
| 2021 | New Product Approvals | In January, the company received approval from Japan's Ministry of Health, Labour and Welfare for Cwellex for the treatment of Graft versus host disease. |
Competitor Comparison
| Key Parameters | Mallinckrodt Plc | Bayer AG | Merck & Co Inc | Eli Lilly and Co | Johnson Matthey Plc |
|---|---|---|---|---|---|
| Headquarters | Ireland | Germany | United States of America | United States of America | United Kingdom |
| City | Dublin | Leverkusen | Whitehouse Station | Indianapolis | London |
| State/Province | - | Nordrhein-Westfalen | New Jersey | Indiana | - |
| No. of Employees | 2,800 | 100,753 | 68,000 | 35,000 | 14,421 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark Trudeau | Chief Executive Officer; President; Director | Executive Board | 2013 | 60 |
| Bryan M. Reasons | Executive Vice President; Chief Financial Officer | Senior Management | 2019 | 53 |
| Mark J. Casey | Chief Legal Officer; Executive Vice President | Senior Management | 2019 | 58 |
| Brandi Robinson | Senior Vice President; Chief Communications Officer | Senior Management | - | - |
| Tunde Otulana, M.D. | Chief Medical Officer; Senior Vice President | Senior Management | 2016 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer